1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • November 2016
  • 71 pages
  • ID: 4406703
  • Format: PDF
  • By Cancer Research Analytics

Summary

Table of Contents

Search Inside

Description
“Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the fouth-largest oncology drug by 2015 sales.
Revlimid is the largest drug in Celgene’s portfolio and falls in targeted therapy, under the im-munomodulator class of drugs. It is indicated for the treatment of multiple myeloma, myelo-dysplastic syndrome and mantle cell lymphoma and further clinical trials are on for different types of lymphoma, which are estimated to generate strong sales post approvals until the drug’s expiry.


The report gives the basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Revlimid, infor-mation on comptetitor drugs, litigations, number of clinical trials (by year and by phase), and so on.
The report gives an analysis of the historical annual sales (from 2005-2015), historical quarter-ly sales (Q1-2012 to Q3-2016) and sales expectations (from 2016-2021). The analysis broadly indicates that the drug has had strong sales over the past decade and is expected to continue because of the advantage of efficacy and pending approvals. Cumulatively, this drug has seen sales of USD 33 bn since its launch.


Details of the sales analysis section

Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2005-2015. The report has all the data in tabular for-mat as well. We have highlighted key reasons for the sales trend in all the geographies listed.

Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past 19 quarters from Q1-2012 to Q3-2016. The quarterly data is also in graph-ical as well as tabular format.

Expected sales analysis: The report has our expectations for Revlimid sales over 2016-2021. We have highlighted the key reasons for our expectations. All the historical as well as ex-pected sales analysis is based on:
(1) Total global sales
(2) US sales
(3) International sales


Other important details

Key event tracker: The report highlights key events that have taken place for Revlimid from 2005 to 2016 (along with those events expected in 2016). It gives additional information about the key events that have driven sales for the drug over this period.
Clinical trial numbers: The report provides numbers of clinical trials which have started for Revlimid in 2016, 2015 and 2014 and for different phases: phase-III, phase-III/II and phase-II. It gives insights into whether the company is still spending money for taking the drug even fur-ther for other indications or for use in combination therapies.
Comptetive drugs: Additionally, all the drugs which compete/can compete with Revlimid in its different markets such as multiple myeloma (MM), newly diagnosed multiple myeloma (NDMM), myelodysplastic syndrome (MDS), mantle cell lymphoma (MCL), etc., are listed with their details including brand name, API, company, class of drug, therapy class and treatment preference.
Litigations: We have given details of the ongoing litigation/cases of Celgene over Revlimid.
News: We have listed news related to Revlimid that would impact the drug’s performance.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019SummaryBaculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target ...

Breast Cancer Treatment Drug Markets in China

Breast Cancer Treatment Drug Markets in China

  • $ 4000
  • July 2019

China’s demand for Breast Cancer Treatment Drug has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019SummaryTumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Recepto ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on